CETP I405V — The Longevity Lipid Variant
Cholesteryl ester transfer protein (CETP) is the molecular shuttle that moves cholesterol esters from
HDL to LDL and VLDL, simultaneously transferring triglycerides in the opposite direction. This exchange
is a central step in reverse cholesterol transport — the process by which excess cholesterol is harvested
from peripheral tissues and returned to the liver for excretion. High CETP activity tends to lower HDL
levels and shrink HDL particle size; low CETP activity allows HDL to accumulate as larger, more
cholesterol-rich particles.
The I405V variant at rs5882 sits in exon 14 of the CETP gene | located on chromosome 16q13, encoding
a 476-amino-acid secreted glycoprotein. Unlike the TaqIB
variant (rs708272), which is a non-functional intronic marker in linkage with the functional haplotype,
I405V is a direct coding change — substituting isoleucine (Ile) for valine (Val) at mature-protein
position 405 (precursor position 422). This direct amino acid substitution reduces CETP secretion from
hepatocytes and lowers circulating CETP protein levels.
The Mechanism
At the molecular level, the Val allele (G on the plus strand) reduces CETP protein expression. Carriers
of the Val allele have measurably lower serum CETP concentrations: in the original Barzilai cohort, VV
centenarians showed CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers
(p=0.01). Lower CETP activity allows HDL particles to
retain their cholesteryl ester cargo longer, producing larger, more buoyant HDL2 particles and elevating
total HDL-C. Studies suggest VV carriers tend to have higher HDL-C levels, with the effect more
pronounced in women.
The relationship between I405V and cognitive health has a plausible mechanism: HDL particles deliver
cholesterol to the brain through the blood–brain barrier, and larger, lipid-rich HDL particles may
support neuronal membrane integrity and myelin maintenance. Reduced CETP activity may also lower
apolipoprotein B–containing particles in cerebrospinal fluid, decreasing amyloid deposition.
The Evidence
The landmark study was Barzilai et al., JAMA 2003, which
genotyped 213 Ashkenazi Jewish centenarians (mean age 98.2 years), 216 of their offspring, and 258
age-matched controls. Centenarians and their offspring showed 2.9- to 3.6-fold enrichment (in men) and
1.5- to 2.7-fold enrichment (in women) for the VV genotype compared to controls, alongside larger HDL
and LDL particle sizes, lower hypertension prevalence, and lower rates of metabolic syndrome.
The longevity-cognition link was formalized in Barzilai et al., Neurology 2006
: among cognitively intact centenarians (MMSE >25),
29% were VV vs only 14% of those with MMSE ≤25 (p=0.02). In a younger cohort (Einstein Aging Study),
VV subjects showed a fivefold increase compared to expected frequency. The most quantitatively precise
evidence comes from Sanders et al. 2010: following 523
older adults for a mean 4.3 years, VV homozygotes showed significantly slower memory decline (p=0.03) and dramatically
lower dementia risk (HR 0.28, 95% CI 0.10–0.85, p=0.02) and Alzheimer's disease risk (HR 0.31, 95% CI
0.10–0.95, p=0.04). The large Cache County Study, with
4,486 subjects followed over 12 years, found each additional Val allele associated with 0.6-point/year
slower cognitive decline (p=0.011).
Importantly, this picture is not universal. Yu et al. 2012
found the opposite in 1,384 European-ancestry participants: VV genotype was associated with faster
cognitive decline and higher AD risk (HR 1.63). A Chinese case-control meta-analysis
across 8 studies found the V
allele was protective in Ashkenazi Jews (OR 1.46) but a risk allele in East Asian populations (OR 0.67).
The APOE interaction may partly explain this: in APOE ε4
carriers, the V allele associates with preserved cortical thickness; in non-carriers, the I allele is
protective. The cardiovascular evidence is similarly mixed — the Val allele reliably raises HDL but does
not consistently reduce cardiovascular events, mirroring failures of CETP inhibitor drugs in clinical
trials.
Practical Actions
For GG (VV) carriers, the primary implication is the established HDL-raising effect: monitor HDL
particle size (not just HDL-C) to confirm the phenotypic benefit, and support it through dietary
choices known to synergize with endogenous CETP inhibition. Plant sterols (2 g/day) significantly
lower triglycerides in GG individuals specifically, with no effect in other genotypes — making this a
targeted dietary intervention. Niacin also raises HDL and reduces CETP activity, potentially amplifying
the GG genotype's effect.
For AA (II) carriers, HDL-C and HDL particle size are worth monitoring, as higher CETP activity tends
to produce smaller, denser HDL particles. Dietary strategies that modulate CETP activity — plant
sterols, omega-3 fatty acids, moderate alcohol avoidance — may partially compensate for the higher
CETP burden.
Interactions
The most clinically relevant interaction is with APOE genotype. The APOE ε4 allele independently
raises Alzheimer's disease risk and alters lipid metabolism. In APOE ε4 carriers, the CETP Val allele
appears to protect against medial temporal lobe atrophy; in non-carriers, the Ile allele is paradoxically
protective. This complex interaction suggests that CETP I405V genotype should be interpreted alongside
APOE status, and the net effect on neurological risk depends substantially on APOE background.
The rs708272 TaqIB variant (in the heart-inflammation category) is in strong linkage disequilibrium
with rs5882 in European populations, and these two markers tag the same functional haplotype. Both
should not be used simultaneously to predict CETP activity — I405V (rs5882) is the direct functional
variant, while TaqIB is a proxy.
All Genotypes
Normal CETP activity and standard HDL particle profile
You carry two copies of the Isoleucine allele (A on the plus strand), the more common variant in most populations. Your CETP protein is fully active at normal levels, producing the typical exchange of cholesterol esters between HDL and LDL particles. About 42% of people of European descent share this genotype. This is the baseline from which the Val allele's effects are measured — your HDL levels and particle sizes follow normal population distributions.
Val/Val genotype — reduced CETP activity, enlarged HDL particles, and centenarian enrichment
You carry two copies of the Valine allele (GG), the genotype found at 2.9- to 3.6-fold higher frequency in Ashkenazi Jewish centenarians compared to controls, and associated with lower serum CETP levels, higher HDL-C, and larger lipoprotein particles. About 12% of people of European descent share this genotype. Multiple independent studies associate GG with slower cognitive decline in aging populations, though results are not universal across all ancestries.
One Val allele — moderately elevated HDL and partial CETP reduction
You carry one copy of the longevity-associated Valine allele (G) and one copy of the Isoleucine allele (A). This heterozygous state produces intermediate CETP activity — lower than II individuals but not as reduced as GG. About 46% of people of European descent share this genotype. You likely have modestly higher HDL-C and larger HDL particles compared to AA carriers, though the effect is less pronounced than in GG homozygotes.